1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
HOME > LATEST
LATEST
-
ORGANIZATION Create NDA Category Modeled after FDA’s “505(b)(2)” Pathway: JEMA
February 20, 2025
-
REGULATORY Ex-Lawmakers Launch Council for Revamping Japan’s Drug Innovation
February 20, 2025
-
REGULATORY Chuikyo OKs Pricing Rules for FY2025 Drug Price Revision
February 20, 2025
-
REGULATORY CDP Submits Bill Calling for Outright Freeze on Copay Cap Reform
February 20, 2025
-
BUSINESS Kaken Set to Take Stab at US Market with Vascular Malformation Drug
February 20, 2025
-
BUSINESS Pfizer Japan to Discontinue Amoxapine after Carcinogen Issue
February 20, 2025
-
REGULATORY Sakigake Tag Withdrawn for 2 Boehringer Drugs
February 20, 2025
-
REGULATORY Pfizer Pulls Japan NDA for Hemophilia Gene Therapy Beqvez as Program Called Off Globally
February 20, 2025
-
BUSINESS LTL Pharma Sees 30% Drop in Gaster Sales after New LLP Coverage Rollout
February 19, 2025
-
REGULATORY Ishiba Vows to Take Steps on OTC-Like Meds from FY2026, Freeze Certain Hikes in Copay Caps
February 19, 2025
-
REGULATORY Japan Cabinet OKs 5-Year Healthcare Strategy from FY2025
February 19, 2025
-
REGULATORY Minister Touts “Balanced” Off-Year Revision after USCC Letter
February 19, 2025
-
BUSINESS CureApp’s Alcoholism Therapy App Approved in Japan
February 19, 2025
-
BUSINESS Japan Approves Shionogi’s Therapy App for Pediatric ADHD
February 19, 2025
-
BUSINESS Kyorin Nabs Japan Option for Cyrano’s Post-Viral Smell Loss Drug
February 19, 2025
-
BUSINESS COVID Shot Kostaive Lands EU Approval, 1st Nod Outside Japan
February 19, 2025
-
BUSINESS Boehringer Files Zongertinib in Japan for HER2 Lung Cancer
February 19, 2025
-
BUSINESS Deciphera’s Rare Tumor Drug Grabs US Approval
February 19, 2025
-
REGULATORY Espha’s Januvia Generic on Approval Roster towards June Listing
February 18, 2025
-
REGULATORY “Annual Reports” Allowed for CMC Changes with Minimal Impact: MHLW
February 17, 2025
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…